Loading provider…
Loading provider…
Hematology & Oncology Physician in Tampa, FL
NPI: 1104025592Primary Employer
Moffitt Medical Group
moffitt.org
HQ Phone
Get M.D. Joseph's Phone Numberphone_androidMobile
Get M.D. Joseph's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
2010 - 2026

American Board of Internal Medicine
Medical Oncology
USF Health Morsani College of Medicine
health.usf.edu
Medical School
Until 2004
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General Hospital
Fellowship • Hematology and Medical Oncology
2007 - 2010
Beth Israel Deaconess Medical Center
Residency • Internal Medicine
2004 - 2007
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 42 | 168 |
Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.
Authors: Claudio Anasetti
Publication Date: 2016-05-08
Regarding “Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study”
Authors: Miguel Perales, Juliet Barker
Publication Date: 2019-08
Lead Sponsor: Marcelo Pasquini, MD
Collaborators: National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Marrow Donor Program, Celgene a wholly owned subsidiary of BMS
Intervention / Treatment: DRUG: Lenalidomide and bb2121
Lead Sponsor: Fred Hutchinson Cancer Center
Intervention / Treatment: OTHER: Questionnaire Administration, OTHER: Quality-of-Life Assessment, DRUG: Placebo Administration, BIOLOGICAL: Ustekinumab
Lead Sponsor: Fred Hutchinson Cancer Center
Collaborators: AstraZeneca
Intervention / Treatment: OTHER: Questionnaire Administration, DRUG: Acalabrutinib